<DOC>
	<DOC>NCT00784862</DOC>
	<brief_summary>To assess the effect of ARIMIDEX on the pharmacokinetics of tamoxifen and the effects of tamoxifen on the pharmacokinetics of ARIMIDEX..</brief_summary>
	<brief_title>ATAC - Pharmacokinetics (PK) Sub-Protocol</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Eligible for entry into the main ATAC trial 1033IL/0029 Patients must have been taking ATAC trial medication for at least 3 months (i.e. patients must have reached at least visit 2 of the main ATAC study) Patients should be taking their medication in the mornings for at least 3 months Patients must be 100% compliant over the preceding fourteen days Excluded from entry into the main ATAC trial (1033IL/0029) Patients whose concurrent treatment includes diazepam or drugs which might affect tamoxifen steady state levels or steroid hormone status. These include ketoconazole (antifungal) or related compounds</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>